리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 09월
페이지 정보:영문 194 Pages
라이선스 & 가격 (부가세 별도)
한글목차
바이러스 클리어런스 세계 시장은 2030년까지 18억 달러에 이를 전망
2023년에 5억 6,620만 달러로 추정되는 바이러스 클리어런스 세계 시장은 분석 기간인 2023-2030년에 18.2%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 18억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 재조합 단백질 용도는 CAGR 18.6%를 나타내고, 분석 기간 종료시에는 4억 3,040만 달러에 이를 것으로 예측됩니다. 혈액 및 혈액제제 용도의 성장률은 향후 7년간 CAGR로 16%로 추정됩니다.
미국 시장은 1억 7,860만 달러로 추정, 중국은 CAGR17.9%로 성장 예측
미국 바이러스 클리어런스 시장은 2023년에는 1억 7,860만 달러에 이른 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2023년부터 2030년까지 분석 기간에 17.9%의 연평균 복합 성장률(CAGR)로 성장을 지속하여, 2030년까지 3억 1,920만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서 일본과 캐나다가 있으며, 각각 2023-2030년간16%로 15.2%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 12.6%로 성장할 것으로 예측됩니다.
2024년 신규 보고서의 특징
인플루언서 참여 통계에 대한 전체 액세스 권한
디지털 아카이브 및 "MarketGlass" 리서치 플랫폼에 무료로 액세스하세요. 전 세계 도메인 전문가들의 창의성과 시장 지식을 응집력 있고 협업적인 방식으로 활용할 수 있는 독점적인 MarketGlass 플랫폼이 완벽하게 지원됩니다. 당사의 최첨단 도구는 참가자의 개인정보와 신원을 보호하면서 세계적 수준의 시장 관점을 제공합니다. 보고서의 수치, 통계 및 시장 설명은 해당 분야의 전문가와 인플루언서가 공유한 엄선된 인사이트를 기반으로 합니다.
실시간 데이터 시뮬레이터 도구 및 맞춤형 보고서 생성 기능과 함께 제공되는 대화형 설문지에 참여할 있습니다.
기업 간 스마트한 의견 교환을 위한 동료 협업 및 대화형 플랫폼에 대한 전체 클라이언트 액세스 권한 부여
금융긴축과 그에 따른 금리 상승에 의한 지정학적인 영향과 경제 불안정성이 2024년 세계 경제에 파란을 가져올 것으로 예상됩니다. 중동의 적대 행위와 점점 더 빈번해지는 기후 재난 등 여러 요인이 복구의 길에 계속 압력을 가할 것입니다. 이러한 리스크 가운데 디스인플레이션의 조짐과 고질적인 인플레이션에 대한 불안감 완화, 공급망 정상화, 에너지 비용의 변동성에도 불구하고 가격 조정 등 몇 가지 긍정적인 요소도 구체화되고 있습니다. 인도나 미국을 비롯한 G21 국가 선거는 자본 흐름이나 투자 전략에 영향을 미칠 가능성이 있습니다. 인도가 글로벌 투자 환경에서 매력적인 투자처로 부상하고 있지만, 미국에 기반을 둔 기술 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속해서 우위를 점할 것입니다. 실리콘밸리와 그 밖의 지역의 기술 기회는 둔화되기는 했지만 회복세를 보이고 있는 국내 경제와 우호적인 규제 환경에 힘입어 고성장 전망을 추구하는 투자자들에게 여전히 매력적입니다. 유럽은 금융긴축 정책과 경기후퇴 리스크와의 싸움이 계속 되지만, 영국은 전망이 가장 어둡고, 2024년 경기후퇴 리스크가 가장 높습니다. 중국은 정부 지출과 소비자 지출의 개선에 힘입어 성장에 대한 희망을 품고 있는 와일드카드로 남아 있습니다. 변동성이 큰 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 제공할 것입니다. 투자 결정을 내릴 때 민첩성과 전략적 선견지명과 함께 변동성을 성장의 촉매제로 받아들이는 것이 생존을 위해 여전히 중요할 것입니다.
Global Viral Clearance Market to Reach $1.8 Billion by 2030
The global market for Viral Clearance estimated at US$566.2 Million in the year 2023, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 18.2% over the analysis period 2023-2030. Recombinant Proteins Application, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$430.4 Million by the end of the analysis period. Growth in the Blood and Blood Products Application segment is estimated at 16% CAGR for the next 7-year period.
The U.S. Market is Estimated at $178.6 Million, While China is Forecast to Grow at 17.9% CAGR
The Viral Clearance market in the U.S. is estimated at US$178.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$319.2 Million by the year 2030 trailing a CAGR of 17.9% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16% and 15.2% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Viral Clearance - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World 7-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
TABLE 3: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 4: World 7-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Blood and Blood Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World 7-Year Perspective for Blood and Blood Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World 7-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 9: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 10: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World 7-Year Perspective for Pharmaceutical & Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 15: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 16: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 19: World Viral Clearance Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: USA 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 22: USA Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 23: USA 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
CANADA
TABLE 24: Canada Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 25: Canada 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
JAPAN
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 28: Japan Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 29: Japan 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 30: Japan Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 31: Japan 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
CHINA
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 32: China Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: China 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 34: China Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 35: China 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
EUROPE
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 36: Europe Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 37: Europe 7-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
TABLE 38: Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Europe 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 40: Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 41: Europe 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
FRANCE
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 42: France Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 43: France 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 44: France Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: France 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
GERMANY
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 46: Germany Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 47: Germany 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 48: Germany Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 49: Germany 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
ITALY
TABLE 50: Italy Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Italy 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 52: Italy Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 53: Italy 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
UNITED KINGDOM
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 54: UK Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 55: UK 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 56: UK Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: UK 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
REST OF EUROPE
TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 59: Rest of Europe 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 61: Rest of Europe 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
ASIA-PACIFIC
Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Asia-Pacific 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 65: Asia-Pacific 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
REST OF WORLD
TABLE 66: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 67: Rest of World 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
TABLE 68: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Rest of World 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
